AlcaSynn Pharmaceuticals

AlcaSynn Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative non-opioid treatments for chronic pain management. The company's lead candidate, ALC-101, is a proprietary topical formulation designed to provide localized relief for neuropathic pain conditions such as post-herpetic neuralgia and diabetic peripheral neuropathy. By utilizing advanced drug delivery technologies, AlcaSynn aims to improve the efficacy and safety profile of existing analgesic agents while minimizing systemic side effects. The company is headquartered in Sherbrooke, Quebec, and primarily utilizes the 505(b)(2) regulatory pathway to accelerate the development of its therapeutic pipeline. AlcaSynn's mission is to address the significant unmet need for effective, non-addictive pain relief options in the global healthcare market.